Significant increase in progression-free survival

Significant increase in progression-free survival when adding elotuzumab to pomalidomide/dexamethasone in the treatment of previously treated multiple myeloma.

ELOQUENT-3: Addition of Elotuzumab to Pomalidomide and Dexamethasone in Previously Treated Multiple Myeloma